Navigation Links
New Study Demonstrates Ramelteon Does Not Exacerbate Respiratory Depressant Effects in Patients With Moderate-to-Severe COPD
Date:12/3/2007

ORLANDO, Fla., Dec. 3 /PRNewswire/ -- A new study presented today showed that ramelteon did not exacerbate respiratory depressant effects in patients (40 years and older) with moderate to severe chronic obstructive pulmonary disease (COPD), as measured by oxygenation or abnormal breathing events relative to placebo. Results of this double-blind, placebo-controlled trial were presented at the 53rd International Respiratory Congress of the American Association for Respiratory Care.

"Getting adequate sleep is essential to maintaining health in people who live with COPD. These results suggest that ramelteon is a sleep medication that can be used safely in adults suffering from moderate to severe COPD who are concerned with breathing impairment during sleep," said Thomas Roth, PhD, director, Henry Ford Sleep Research and Disorders Center. "While traditional sleep aids can negatively affect respiration during sleep in patients with COPD, this study demonstrated that ramelteon does not produce such respiratory depressant effects."

According to the National Institutes of Health, more than 12 million Americans are currently diagnosed with COPD. It is the fourth leading cause of death in the United States and causes serious, long-term disability.

"Patients with COPD -- usually characterized by a combination of chronic bronchitis and emphysema -- must take extreme care in ensuring they receive enough oxygen at all times, particularly when sleeping. Other medications used for insomnia may reduce upper airway muscle tone, which can lead to increased hypoxemia," said Dr. Roth. "This study shows that there was no difference in blood oxygen saturation all night between placebo and ramelteon."

Study Design

A total of 25 adults age 40 or older with moderate to severe COPD were randomized to receive ramelteon 8 mg or placebo 30 minutes before overnight monitoring of oxygen saturation (SaO2) by pulse oximetry and sleep by polysomnography. After
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... In ... filed against Johnson & Johnson report that a new location for pretrial proceedings ... regular news updates and cancer warning information at their website, the Talcum Powder ...
(Date:8/4/2015)... ... August 04, 2015 , ... Nathan’s Famous was recently ... small, medium, and large businesses making an impact in their industry. Andrew Tropeano, the ... how the famous hot dog maker now offers a 50% Reduced Fat All-Beef ...
(Date:8/4/2015)... Palm Coast, Florida (PRWEB) , ... August 04, ... ... Daiichi Sankyo Inc have awarded independent educational grants in support of an interaction ... Prevention and DVT/PE." The activity is jointly provided by Medical Learning Institute Inc. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Please join us for the ... Sunday, September 20th at Oneida Shores Park in Brewerton, NY. , Doris Connor ... brain aneurysm at the young age of 59. Her family and friends have since ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... a state-of-the-art digital press at its Denver facility that will usher in a ... will help Lightning Labels more effectively meet its twin objectives of ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 2Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 3Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 2Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 3Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 2Health News:4th Annual Doris A. Connor Memorial Event for Brain Aneurysm Awareness to be Held in Brewerton, NY with Proceeds Benefitting Renowned Brain Aneurysm Foundation 3Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3
... March issue of Neurology, the epilepsy drug Valproate has been ... ,For pregnant women with epileptic seizures, often the ... who took the drug in their first trimester of pregnancy ... the study was collected from pregnant women in US and ...
... has for decades focused on finding the underlying genetic ... genes themselves are controlled by components outside the nucleus ... microenvironment," said researcher Maniotis. ,Research finding at ... malignancy also depends on the molecules that surrounds the ...
... adding the drug rasagiline to standard treatment with levodopa ... patients spend suffering from motor fluctuations they experience during ... once-daily oral rasagiline to the drug entacapone, which must ... in around 690 patients. Both of the additional drugs ...
... able to monitor their blood sugar around the clock without ... ,A new device that measures blood sugar by testing ... out by a transdermal low-level electric current -- and then ... effective even in children under age 7. ,Studies were ...
... to suggest that supplementing the diet with vitamin E ... study published In Journal Of American Medical association, says ... something very different. ,The researchers had studied ... or HOPE centers between 1993 and 1999, and the ...
... says that oil from the fishes contains a property that ... Salmon, if are taken in a diet supplemented by low ... disease and arthritis. In case of absence of fish, a ... trick. ,Trials have shown previously that omega-3 fatty acids ...
Cached Medicine News:Health News:Cell’s microenvironment linked to cancer 2
(Date:8/3/2015)... 3, 2015  CytRx Corporation (NASDAQ: CYTR ), ... today reported financial results for the three months ended ... recent accomplishments and upcoming milestones for its clinical development ... been very productive for CytRx. Enrollment in our ongoing ... soft tissue sarcoma (STS) continues on track to be ...
(Date:8/3/2015)... Colo., Aug. 3, 2015  Array BioPharma Inc. ... the fourth quarter and full year of its ... Ron Squarer, Chief Executive Officer of Array, noted, "Binimetinib ... 3, are on track for regulatory submissions in ... BRAF-mutant melanoma and BRAF-mutant colorectal cancer further validate ...
(Date:8/3/2015)... 2015 Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: ... Teper , will present live at VirtualInvestorConferences.com on August ...   11:30AM EDT LINK:    http://tinyurl.com/aug6-pre-imnp ... where investors are invited to ask the company questions ... well as the association,s "virtual trade booth." If attendees ...
Breaking Medicine Technology:CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2
... May 12 Huntington Bank (Nasdaq: HBAN ... to finance a $25 million electronic medical records ... care providers, Zanesville -based Genesis HealthCare System. The ... information system enabling Genesis to establish an EMR across its ...
... May 12 /PRNewswire-Asia-FirstCall/ -- China Biologic,Products, Inc. (Nasdaq: CBPO ... China , today announced that its,majority-owned subsidiary, Shandong Taibang Biological ... Health,Department to build two new plasma stations. , ... "This approval ...
Cached Medicine Technology:Huntington Financing Package Supports Major Regional Medical Center Electronic Medical Records Project 2China Biologic Products to Build Two New Plasma Stations in Shandong Province 2China Biologic Products to Build Two New Plasma Stations in Shandong Province 3China Biologic Products to Build Two New Plasma Stations in Shandong Province 4
... contrast agent approved for sale in the ... the Amersham Health portfolio to include an ... aids in the detection, localization, characterization, and ... within minutes of injection, and additional scans ...
... new Contrast Agent for Ultrasonography ... stabilized SF6 microbubbles. The size ... 1 and 10 m, and ... and 5 x 108 per ...
... is the only isosmolar contrast medium (IOCM™) available ... that of blood, VISIPAQUE was designed for patient ... contrast medium formulated with sodium and calcium in ... received FDA approval for use in children over ...
The cordless Simon Dermatome with rechargeable battery is used to harvest split-thickness skin grafts and for debridement....
Medicine Products: